Radius Health has announced the locations for its RAD011 SCOUT-015 Clinical Trials. Below, you will find a downloadable map with each participating hospital and medical center around the country.
The RAD011 SCOUT-015 studies are in various stages, depending on the location, from initiated to activated and ready to enroll. You can also find a comprehensive list of these RAD011 trial sites at www.clinicaltrials.gov. If you are interested in enrolling your loved one with Prader-Willi syndrome (PWS), please contact a specific location on the below list to begin the process. You can also reach out to firstname.lastname@example.org with any questions about the SCOUT-15 trial.
About RAD011 and the SCOUT-015 Clinical Trial
Radius Health's RAD011 is a synthetic cannabidiol oral solution, which is being studied as a possible treatment for hyperphagia and related behaviors in Prader-Willi syndrome. Earlier this year, Radius Health released a fact sheet about its SCOUT-015 clinical trial.
According to Radius Health, the SCOUT-015 clinical study is a "global randomized, double-blind, placebo-controlled study in PWS with around 200 patients, and a seamless phase 2/3 design to allow for evaluation of multiple dose groups and Intent-To-Treat efficacy analysis with both Phase 2 and Phase 3 cohorts."
You can download the RAD011 Fact Sheet by clicking here.